Phio signs U.S. cGMP manufacturing deal for PH-762 clinical, commercial supply

Reuters03-30

Phio signs U.S. cGMP manufacturing deal for PH-762 clinical, commercial supply

Phio Pharmaceuticals signed a cGMP drug product manufacturing services agreement with a U.S. manufacturer to supply PH-762 for future clinical trials.
Deal covers production of PH-762 for both clinical supply and commercial supply.
PH-762 is Phio’s lead intratumoral siRNA candidate for cutaneous carcinomas, targeting PD-1 gene silencing.
Phase 1b trial reported 22 patients treated across five dose-escalation cohorts with no dose-limiting toxicities or serious adverse events.
Phio reported about 65% pathological response rate in cutaneous squamous cell carcinoma across cohorts, including 85% in highest-dose cohort.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603300700NEWSFILECNPR____20260330_290314_1) on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623930311?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623930311","market":"us","top_or_hot":-1,"title":"Phio signs U.S. cGMP manufacturing deal for PH-762 clinical, commercial supply","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Phio signs U.S. cGMP manufacturing deal for PH-762 clinical, commercial supply\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          <a href=\"https://laohu8.com/S/PHIO\">Phio Pharmaceuticals</a> signed a cGMP drug product manufacturing services agreement with a U.S. manufacturer to supply PH-762 for future clinical trials.\n        </li>\n<li>\n          Deal covers production of PH-762 for both clinical supply and commercial supply.\n        </li>\n<li>\n          PH-762 is Phio’s lead intratumoral siRNA candidate for cutaneous carcinomas, targeting PD-1 gene silencing.\n        </li>\n<li>\n          Phase 1b trial reported 22 patients treated across five dose-escalation cohorts with no dose-limiting toxicities or serious adverse events.\n        </li>\n<li>\n          Phio reported about 65% pathological response rate in cutaneous squamous cell carcinoma across cohorts, including 85% in highest-dose cohort.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603300700NEWSFILECNPR____20260330_290314_1) on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Phio signs U.S. cGMP manufacturing deal for PH-762 clinical, commercial supply</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhio signs U.S. cGMP manufacturing deal for PH-762 clinical, commercial supply\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-30 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Phio signs U.S. cGMP manufacturing deal for PH-762 clinical, commercial supply\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          <a href=\"https://laohu8.com/S/PHIO\">Phio Pharmaceuticals</a> signed a cGMP drug product manufacturing services agreement with a U.S. manufacturer to supply PH-762 for future clinical trials.\n        </li>\n<li>\n          Deal covers production of PH-762 for both clinical supply and commercial supply.\n        </li>\n<li>\n          PH-762 is Phio’s lead intratumoral siRNA candidate for cutaneous carcinomas, targeting PD-1 gene silencing.\n        </li>\n<li>\n          Phase 1b trial reported 22 patients treated across five dose-escalation cohorts with no dose-limiting toxicities or serious adverse events.\n        </li>\n<li>\n          Phio reported about 65% pathological response rate in cutaneous squamous cell carcinoma across cohorts, including 85% in highest-dose cohort.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603300700NEWSFILECNPR____20260330_290314_1) on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHIO","symbol_name":"Phio Pharmaceuticals","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL3DpXjG:1","article_id":"2623930311","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623930311","pubTimestamp":1774868609,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Phio Pharmaceuticals signed a cGMP drug product manufacturing services agreement with a U.S. manufacturer to supply PH-762 for future clinical trials.Deal covers production of PH-762 for both clinical supply and commercial supply.PH-762 is Phio’s lead intratumoral siRNA candidate for cutaneous carcinomas, targeting PD-1 gene silencing.Phase 1b trial reported 22 patients treated across five dose-escalation cohorts with no dose-limiting toxicities or serious adverse events.Phio reported about 65% pathological response rate in cutaneous squamous cell carcinoma across cohorts, including 85% in highest-dose cohort.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHIO":"Phio Pharmaceuticals","BK4139":"生物科技"},"translate_title":"Phio签署PH-762临床和商业供应的美国cGMP制造协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHIO":0.9},"content_text":"Phio signs U.S. cGMP manufacturing deal for PH-762 clinical, commercial supply\n    \n\n\nPhio Pharmaceuticals signed a cGMP drug product manufacturing services agreement with a U.S. manufacturer to supply PH-762 for future clinical trials.\n        \n\n          Deal covers production of PH-762 for both clinical supply and commercial supply.\n        \n\n          PH-762 is Phio’s lead intratumoral siRNA candidate for cutaneous carcinomas, targeting PD-1 gene silencing.\n        \n\n          Phase 1b trial reported 22 patients treated across five dose-escalation cohorts with no dose-limiting toxicities or serious adverse events.\n        \n\n          Phio reported about 65% pathological response rate in cutaneous squamous cell carcinoma across cohorts, including 85% in highest-dose cohort.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603300700NEWSFILECNPR____20260330_290314_1) on March 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623930311","isCrawlerRequest":true}